The drug candidate RBD3133, which targets the INHBE gene, is heading into human safety trials for obesity.
Live Poll
Do you believe the development of new obesity medications is moving in the right direction?
October 7, 2026
Digital Tools and Meals Have Slowed Post-GLP-1 Weight RegainAdults who stopped GLP-1 medications saw slower weight regain using structured meal plans or digital apps.
October 7, 2026
Experimental Injection Reduced Visceral Fat in Phase 2 TrialsAdults receiving the drug CBL-514 saw a decrease in visceral fat compared to those given a placebo.
October 7, 2026
Ketohexokinase Inhibitor Improved Liver Insulin SensitivityA new trial shows that targeting fructose metabolism may help reduce liver fat in adults with fatty liver disease.
October 7, 2026
WHO Has Advised Against Obesity Drugs for Young ChildrenThe recommendation applies to children under 10, citing limited evidence on long-term safety.
October 6, 2026
Semaglutide Reduced Liver Fat in Obesity StudyAdults with obesity saw significant reductions in liver fat after 72 weeks of treatment with semaglutide.
October 5, 2026
Ultrasound Mapped Adipocyte Size in Lymphedema PatientsNew research suggests ultrasound grades may offer insights into tissue changes for those managing lymphedema.
October 4, 2026
Model Revealed Weight Loss via GLP-1 MedicationBrooks Nader disclosed using GLP-1 therapy to lose 30 pounds to meet industry requirements.
October 4, 2026
Marley Spoon Launched Meal Kits for GLP-1 UsersThe company introduced a new product line as it responds to shifting consumer demand for weight-loss support.
October 2, 2026
Developer Released New Blender Weight Painting ToolThe cvELD Edit Paint add-on for Blender now includes enhanced gradient features for multi-bone weight adjustment.
October 1, 2026
Obesity Drug Survodutide Cut Weight and HbA1c LevelsIn a clinical trial, patients with obesity and type 2 diabetes saw significant weight and blood sugar reductions.
